Cover Image

NPS+:類風濕性關節炎 (歐盟5國)

NPS+ Rheumatoid Arthritis (EU5)

出版商 FirstWord 商品編碼 351849
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
NPS+:類風濕性關節炎 (歐盟5國) NPS+ Rheumatoid Arthritis (EU5)
出版日期: 2016年09月01日 內容資訊: 英文

本報告依據法國、義大利、德國、西班牙、英國的150名風濕醫生的調查結果,提供類風濕性關節炎的領導品牌藥的醫生使用趨勢和各種見解彙整,支援客戶的忠誠度的NPS (淨推薦值) 指標的改善。


  • 市場2大品牌遙遙領先
  • 生技仿製藥產品低迷但有希望
  • 滿意度尚可但低忠誠度
  • 中端市場的被動潛力
  • 臨床性問題最優先


  • RoActemra (tocilizumab; Roche)
  • Benepali (etanercept; Biogen)
  • Cimzia (certolizumab pegol; UCB)
  • Enbrel (etanercept; Pfizer)
  • Humira (adalimumab; AbbVie)
  • Inflectra (infliximab; Pfizer)
  • Orencia (abatacept; BMS)
  • Remicade (infliximab; Merck Sharpe & Dohme)
  • Remsima (infliximab; Mundipharma, Napp, Kern Pharma, Biogaran)
  • MabThera (rituximab; Roche)
  • Simponi (golimumab; Merck Sharpe & Dohme)



  • 類風濕性關節炎市場的滿意度
  • 風濕醫生對特定品牌藥的忠誠度層級
  • 特定品牌推薦者推薦的其他品牌數
  • 特定品牌推薦者、批判者推薦的其他品牌
  • 在推薦者及批判者間的特定品牌的市場佔有率
  • 如果批判者 成為了推薦者 能得的市場佔有率
  • 推薦者、中立者 (被動式)、批判者對特定品牌的相關訊息
  • 品牌DNA:特定品牌藥相關的風濕醫生自己的話

Net Promoter評分是什麼?

  • NPS的結構
  • NPS的計算方法

關於FirstView的 NPS+


Product Code: 596200694

Two leading brands continue to dominate satisfaction scores. Where does your brand rank?

Few brands are earning high satisfaction scores in the European rheumatoid arthritis (RA) treatment market, but two long-time leaders continue to significantly outperform struggling rivals. Meanwhile, biosimilars are poised for huge market share gains if they can win over detractors.

Based on a survey of 150 rheumatologists, the report builds on the respected net promoter score (NPS), comparing brand loyalty for 11 major RA treatments and highlighting ways you can improve your brand's health-and boost market share-with easy-to-use KPIs.

Top Takeaways

  • Two brands dominate: In a market where only 4 of the 11 surveyed brands have a positive NPS, the two leading brands are way out front, scoring at least twice as high as the nearest competitor. These same two brands dominate the US market as well.
  • Biosimilars are struggling, but there's hope: Despite dismal satisfaction scores, biosimilars are recommended by high numbers of other brands' Promoters and Detractors, and are poised for massive share gains compared to most other brands.
  • Moderate satisfaction, low loyalty: Only about two-thirds of the rheumatologists surveyed are satisfied with available drugs, and few promote one brand exclusively. Loyalty scores and promotion patterns confirm their willingness to switch brands frequently.
  • “Passive” potential in the mid-market: Several brands have high numbers of “Passives” who are closely aligned with Promoters. Winning them over could help several middle-ranking brands push their NPS into positive territory. Find out which brand messages will be most effective.
  • Clinical concerns are the top priorities: Analysis of brand message effectiveness shows that safety, efficacy, and other clinical issues drive more brand recommendations, and resonate with more doctors, than cost concerns. The report reveals which messages are most effective.

Insight into 11 Major Rheumatoid Arthritis Drugs

  • RoActemra (tocilizumab; Roche)
  • Benepali (etanercept; Biogen)
  • Cimzia (certolizumab pegol; UCB)
  • Enbrel (etanercept; Pfizer)
  • Humira (adalimumab; AbbVie)
  • Inflectra (infliximab; Pfizer)
  • Orencia (abatacept; BMS)
  • Remicade (infliximab; Merck Sharpe & Dohme)
  • Remsima (infliximab; Mundipharma, Napp, Kern Pharma, Biogaran)
  • MabThera (rituximab; Roche)
  • Simponi (golimumab; Merck Sharpe & Dohme)

A Report Based on Expert Knowledge

We surveyed 150 rheumatologists from the EU5 (France, Italy, Germany, Spain, UK) , chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.

We conducted the survey between August 1st and 4th, 2016.

Explore Important Brand Loyalty Issues

NPS+ Rheumatoid Arthritis (EU5) explores key issues affecting brand loyalty for drug manufacturers. You'll learn:

  • How satisfied the RA market is.
  • How loyal doctors are to your brand.
  • How many other brands your Promoters recommend.
  • Which other brands your Promoters and Detractors recommend.
  • How much market share your brand has among Promoters and Detractors.
  • How much market share you stand to gain by converting Detractors into Promoters.
  • Which messages Promoters, Passives and Detractors associate with your brand.
  • Your brand DNA: what doctors really think of your brand-in their own words.

What is Net Promoter® Score?

NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?

NPS measures overall brand satisfaction and loyalty by asking one simple question:

"How likely are you to recommend this brand to a colleague?"

Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)-are used to classify respondents into 3 categories:

  • Detractors are those who answer 0 - 6.
  • Passives are those who answer 7 - 8.
  • Promoters are those who answer 9 - 10.

How is NPS calculated?

The percentage of detractors - the percentage of promoters = NPS.

For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.

NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.

What is FirstView NPS+?

NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.

Each NPS+ report examines doctors' relationships with the brands used to treat a major disease area-measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors' own words what brands mean to them.

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

Back to Top